Systemic lupus erythematosus pathophysiology: Difference between revisions
Line 120: | Line 120: | ||
!HLA class2<ref name="pmid12867584">{{cite journal |vauthors=Lee HS, Chung YH, Kim TG, Kim TH, Jun JB, Jung S, Bae SC, Yoo DH |title=Independent association of HLA-DR and FCgamma receptor polymorphisms in Korean patients with systemic lupus erythematosus |journal=Rheumatology (Oxford) |volume=42 |issue=12 |pages=1501–7 |year=2003 |pmid=12867584 |doi=10.1093/rheumatology/keg404 |url=}}</ref> | !HLA class2<ref name="pmid12867584">{{cite journal |vauthors=Lee HS, Chung YH, Kim TG, Kim TH, Jun JB, Jung S, Bae SC, Yoo DH |title=Independent association of HLA-DR and FCgamma receptor polymorphisms in Korean patients with systemic lupus erythematosus |journal=Rheumatology (Oxford) |volume=42 |issue=12 |pages=1501–7 |year=2003 |pmid=12867584 |doi=10.1093/rheumatology/keg404 |url=}}</ref> | ||
| colspan="1" rowspan="1" | | | colspan="1" rowspan="1" | | ||
* Contains [[genes]] encoding [[glycoproteins]] that process and present [[peptides]] for recognition by [[T cells]] (antigen presenting cells) | * Contains [[genes]] encoding [[glycoproteins]] that process and present [[peptides]] for recognition by [[T cells]] ([[Antigen-presenting cell|antigen presenting cells]]) | ||
* The most important related genes: | * The most important related [[Gene|genes]]: | ||
** HLA-DR2 | ** [[HLA-DR2]] | ||
** HLA-DR3 | ** [[HLA-DR3]] | ||
| | | | ||
* Associated with an overall 2 to 3 fold increase in the risk of SLE | * Associated with an overall 2 to 3 fold increase in the risk of SLE | ||
* More in European and Asian | * More in European and Asian | ||
* HLA- | * [[HLA-DQ]] and [[HLA-DR]] alleles: | ||
** Strong association with SLE autoantibodies | ** Strong association with SLE [[autoantibodies]] | ||
|- | |- | ||
!HLA class3<ref name="pmid11079100">{{cite journal |vauthors=Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ |title=Systemic lupus erythematosus, complement deficiency, and apoptosis |journal=Adv. Immunol. |volume=76 |issue= |pages=227–324 |year=2000 |pmid=11079100 |doi= |url=}}</ref> | !HLA class3<ref name="pmid11079100">{{cite journal |vauthors=Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ |title=Systemic lupus erythematosus, complement deficiency, and apoptosis |journal=Adv. Immunol. |volume=76 |issue= |pages=227–324 |year=2000 |pmid=11079100 |doi= |url=}}</ref> | ||
| | | | ||
* Contains important immune genes including: | * Contains important [[Gene|immune genes]] including: | ||
** C2 gene | ** C2 [[gene]] | ||
** C4 gene | ** C4 [[gene]] | ||
** Encode complement proteins | ** Encode [[Complement|complement proteins]] | ||
* The complement system act through opsonization: | * The [[complement system]] act through [[opsonization]]: | ||
** Facilitates the clearance of apoptotic debris and cellular fragments | ** Facilitates the clearance of [[Apoptosis|apoptotic debris]] and cellular fragments | ||
** The fragments | ** The fragments may contain nuclear antigens, which are targets for SLE-associated [[autoantibodies]] | ||
* Complement C4-A has a higher affinity for immune complexes | * [[Complement]] C4-A has a higher affinity for [[immune complexes]] | ||
* Circulating complement C4 proteins clear immune complexes | * Circulating [[complement]] C4 proteins clear [[Immune complex|immune complexes]] | ||
| | | | ||
* Complete C2 and C4 deficiencies: | * Complete C2 and C4 deficiencies: | ||
** Rare | ** Rare | ||
** Associated with a mild form of SLE that affects mostly the joints and skin | ** Associated with a mild form of SLE that affects mostly the [[joints]] and [[skin]] | ||
* Stronger genetic evidence for an association with SLE in C4A than C4-B | * Stronger [[Genetics|genetic]] evidence for an association with SLE in C4A than C4-B | ||
* Circulating complement C4 proteins deficiency will promote autoimmunity | * Circulating complement C4 proteins deficiency will promote [[autoimmunity]] | ||
|- | |- | ||
! rowspan="4" |Non-HLA | ! rowspan="4" |Non-HLA | ||
!Interferon (IFN) regulatory factor 5<ref name="pmid20080916">{{cite journal |vauthors=Löfgren SE, Yin H, Delgado-Vega AM, Sanchez E, Lewén S, Pons-Estel BA, Witte T, D'Alfonso S, Ortego-Centeno N, Martin J, Alarcón-Riquelme ME, Kozyrev SV |title=Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to systemic lupus erythematosus in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells |journal=J. Rheumatol. |volume=37 |issue=3 |pages=574–8 |year=2010 |pmid=20080916 |doi=10.3899/jrheum.090440 |url=}}</ref> | ![[IRF5|Interferon (IFN) regulatory factor 5]]<ref name="pmid20080916">{{cite journal |vauthors=Löfgren SE, Yin H, Delgado-Vega AM, Sanchez E, Lewén S, Pons-Estel BA, Witte T, D'Alfonso S, Ortego-Centeno N, Martin J, Alarcón-Riquelme ME, Kozyrev SV |title=Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to systemic lupus erythematosus in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells |journal=J. Rheumatol. |volume=37 |issue=3 |pages=574–8 |year=2010 |pmid=20080916 |doi=10.3899/jrheum.090440 |url=}}</ref> | ||
| colspan="1" rowspan="1" | | | colspan="1" rowspan="1" | | ||
* Code a transcription factor in the type 1 interferon pathway | * Code a [[transcription factor]] in the type 1 [[interferon]] pathway | ||
* Regulates: | * Regulates: | ||
** Expression of IFN-dependent genes | ** Expression of [[IFN]]-dependent [[genes]] | ||
** Inflammatory cytokines | ** [[Cytokine|Inflammatory cytokines]] | ||
** Genes involved in apoptosis | ** [[Genes]] involved in [[apoptosis]] | ||
| | | | ||
* The most strongly and consistently SLE-associated loci outside the MHC region | * The most strongly and consistently SLE-associated loci outside the [[MHC|MHC region]] | ||
* Upon activation, IRF5 activates transcription of type I IFN and | * Upon activation, [[IRF5]] activates transcription of [[Interferon type I|type I IFN]] and [[proinflammatory]] cytokines such as [[TNFα]], [[IL-12]] and [[IL-6]] | ||
* Specific combinations of several polymorphisms in the | * Specific combinations of several [[polymorphisms]] in the [[IRF5]] region interact to increase disease risk | ||
|- | |- | ||
!STAT4<ref name="pmid18579578">{{cite journal |vauthors=Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O, Eloranta ML, Gunnarsson I, Svenungsson E, Sturfelt G, Bengtsson AA, Jönsen A, Truedsson L, Rantapää-Dahlqvist S, Eriksson C, Alm G, Göring HH, Pastinen T, Syvänen AC, Rönnblom L |title=A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5 |journal=Hum. Mol. Genet. |volume=17 |issue=18 |pages=2868–76 |year=2008 |pmid=18579578 |pmc=2525501 |doi=10.1093/hmg/ddn184 |url=}}</ref><ref name="pmid19109131">{{cite journal |vauthors=Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB |title=Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo |journal=J. Immunol. |volume=182 |issue=1 |pages=34–8 |year=2009 |pmid=19109131 |pmc=2716754 |doi= |url=}}</ref><ref name="pmid18516230">{{cite journal |vauthors=Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA |title=Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus |journal=PLoS Genet. |volume=4 |issue=5 |pages=e1000084 |year=2008 |pmid=18516230 |pmc=2377340 |doi=10.1371/journal.pgen.1000084 |url=}}</ref><ref name="pmid18803832">{{cite journal |vauthors=Kawasaki A, Ito I, Hikami K, Ohashi J, Hayashi T, Goto D, Matsumoto I, Ito S, Tsutsumi A, Koga M, Arinami T, Graham RR, Hom G, Takasaki Y, Hashimoto H, Behrens TW, Sumida T, Tsuchiya N |title=Role of STAT4 polymorphisms in systemic lupus erythematosus in a Japanese population: a case-control association study of the STAT1-STAT4 region |journal=Arthritis Res. Ther. |volume=10 |issue=5 |pages=R113 |year=2008 |pmid=18803832 |pmc=2592800 |doi=10.1186/ar2516 |url=}}</ref> | !STAT4<ref name="pmid18579578">{{cite journal |vauthors=Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O, Eloranta ML, Gunnarsson I, Svenungsson E, Sturfelt G, Bengtsson AA, Jönsen A, Truedsson L, Rantapää-Dahlqvist S, Eriksson C, Alm G, Göring HH, Pastinen T, Syvänen AC, Rönnblom L |title=A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5 |journal=Hum. Mol. Genet. |volume=17 |issue=18 |pages=2868–76 |year=2008 |pmid=18579578 |pmc=2525501 |doi=10.1093/hmg/ddn184 |url=}}</ref><ref name="pmid19109131">{{cite journal |vauthors=Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB |title=Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo |journal=J. Immunol. |volume=182 |issue=1 |pages=34–8 |year=2009 |pmid=19109131 |pmc=2716754 |doi= |url=}}</ref><ref name="pmid18516230">{{cite journal |vauthors=Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA |title=Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus |journal=PLoS Genet. |volume=4 |issue=5 |pages=e1000084 |year=2008 |pmid=18516230 |pmc=2377340 |doi=10.1371/journal.pgen.1000084 |url=}}</ref><ref name="pmid18803832">{{cite journal |vauthors=Kawasaki A, Ito I, Hikami K, Ohashi J, Hayashi T, Goto D, Matsumoto I, Ito S, Tsutsumi A, Koga M, Arinami T, Graham RR, Hom G, Takasaki Y, Hashimoto H, Behrens TW, Sumida T, Tsuchiya N |title=Role of STAT4 polymorphisms in systemic lupus erythematosus in a Japanese population: a case-control association study of the STAT1-STAT4 region |journal=Arthritis Res. Ther. |volume=10 |issue=5 |pages=R113 |year=2008 |pmid=18803832 |pmc=2592800 |doi=10.1186/ar2516 |url=}}</ref> | ||
Line 167: | Line 167: | ||
* Encodes the signal transducer and activator of transcription 4 protein | * Encodes the signal transducer and activator of transcription 4 protein | ||
| | | | ||
* | * Associated with a more severe SLE [[phenotype]]: | ||
** Disease-onset at a young age (<30 years) | ** Disease-onset at a young age (<30 years) | ||
** High frequency of nephritis | ** High frequency of [[nephritis]] | ||
* | * Associated with the presence of [[antibodies]] towards [[Double-stranded DNA helix|double-stranded DNA]] | ||
* | * [[Mutation]] lead to an increased [[sensitivity]] to [[Interferon-alpha|IFN-α]] signaling in peripheral blood [[mononuclear cells]] | ||
|- | |- | ||
!PTPN22<ref name="pmid19302045">{{cite journal |vauthors=Gregersen PK, Olsson LM |title=Recent advances in the genetics of autoimmune disease |journal=Annu. Rev. Immunol. |volume=27 |issue= |pages=363–91 |year=2009 |pmid=19302045 |pmc=2992886 |doi=10.1146/annurev.immunol.021908.132653 |url=}}</ref> | !PTPN22<ref name="pmid19302045">{{cite journal |vauthors=Gregersen PK, Olsson LM |title=Recent advances in the genetics of autoimmune disease |journal=Annu. Rev. Immunol. |volume=27 |issue= |pages=363–91 |year=2009 |pmid=19302045 |pmc=2992886 |doi=10.1146/annurev.immunol.021908.132653 |url=}}</ref> | ||
| | | | ||
* Encodes a lymphoid-specific phosphatase that inhibits T-cell activation | * Encodes a [[lymphoid]]-specific [[Phosphatases|phosphatase]] that inhibits [[T cell|T-cell]] activation | ||
| | | | ||
* Associated with a higher risk of developing multiple autoimmune diseases | * Associated with a higher risk of developing [[Autoimmune disease|multiple autoimmune diseases]] | ||
* | * More seen in European populations | ||
* | * [[Mutation]] increases the intrinsic [[lymphoid]]-specific [[Phosphatases|phosphatase]] activity that lead to: | ||
** Reduced T-cell receptor (TCR) signaling threshold | ** Reduced [[T cell receptor|T-cell receptor (TCR)]] signaling threshold | ||
** Promotes autoimmunity | ** Promotes [[autoimmunity]] | ||
|- | |- | ||
!FcγR genes<ref name="pmid10413210">{{cite journal |vauthors=Yap SN, Phipps ME, Manivasagar M, Tan SY, Bosco JJ |title=Human Fc gamma receptor IIA (FcgammaRIIA) genotyping and association with systemic lupus erythematosus (SLE) in Chinese and Malays in Malaysia |journal=Lupus |volume=8 |issue=4 |pages=305–10 |year=1999 |pmid=10413210 |doi=10.1191/096120399678847876 |url=}}</ref> | !FcγR genes<ref name="pmid10413210">{{cite journal |vauthors=Yap SN, Phipps ME, Manivasagar M, Tan SY, Bosco JJ |title=Human Fc gamma receptor IIA (FcgammaRIIA) genotyping and association with systemic lupus erythematosus (SLE) in Chinese and Malays in Malaysia |journal=Lupus |volume=8 |issue=4 |pages=305–10 |year=1999 |pmid=10413210 |doi=10.1191/096120399678847876 |url=}}</ref> | ||
| | | | ||
* Encode proteins that : | * Encode [[proteins]] that : | ||
** Recognize immune complexes | ** Recognize [[immune complexes]] | ||
** Involved in antibody-dependent responses | ** Involved in [[Antibody-dependent cellular cytotoxicity|antibody-dependent]] responses | ||
| | | | ||
* Mutation associated with: | * [[Mutation]] associated with: | ||
** Low affinity for IgG2-opsonized particles | ** Low affinity for [[Immunoglobulin G|IgG2-opsonized]] particles | ||
** Reduced clearance of | ** Reduced clearance of [[immune complexes]] | ||
|- | |- | ||
! rowspan="5" | | ! rowspan="5" | | ||
!C1q genes<ref name="pmid11079100">{{cite journal |vauthors=Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ |title=Systemic lupus erythematosus, complement deficiency, and apoptosis |journal=Adv. Immunol. |volume=76 |issue= |pages=227–324 |year=2000 |pmid=11079100 |doi= |url=}}</ref> | !C1q genes<ref name="pmid11079100">{{cite journal |vauthors=Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ |title=Systemic lupus erythematosus, complement deficiency, and apoptosis |journal=Adv. Immunol. |volume=76 |issue= |pages=227–324 |year=2000 |pmid=11079100 |doi= |url=}}</ref> | ||
| colspan="1" rowspan="1" | | | colspan="1" rowspan="1" | | ||
* | * The [[complement system]] act through [[opsonization]]: | ||
** | ** Facilitates the clearance of [[Apoptosis|apoptotic debris]] and cellular fragments | ||
** | ** The fragments may contain nuclear antigens, which are targets for SLE-associated [[autoantibodies]] | ||
| | | | ||
Homozygous deficiency of ''C1q | * [[Homozygous]] deficiency of ''C1q'' | ||
* | ** Rare | ||
* Develop a severe and early onset form of SLE | ** Develop a severe and early onset form of SLE | ||
* Associated with severe glomerulonephritis and skin manifestations | ** Associated with severe [[glomerulonephritis]] and [[skin]] manifestations | ||
|- | |- | ||
!The ''IRAK1-MECP2'' region | !The ''IRAK1-MECP2'' region | ||
| | | | ||
* Encode a protein kinase: | * Encode a [[protein kinase]]: | ||
** Regulates multiple pathways in both innate and adaptive immune responses by linking several immune-receptor-complexes to TNF receptor-associated factor 6 | ** Regulates multiple pathways in both [[Innate immune system|innate]] and [[Adaptive immune response|adaptive immune responses]] by linking several immune-receptor-complexes to [[TNF]] receptor-associated factor 6 | ||
** Critical role in the transcriptional suppression of methylation-sensitive genes | ** Critical role in the [[Transcriptional regulation|transcriptional suppression]] of [[methylation]]-sensitive genes | ||
| | | | ||
|- | |- | ||
!TREX1 | !TREX1 | ||
| | | | ||
* Encodes a major exonuclease: | * Encodes a major [[exonuclease]]: | ||
** Proofreads DNA polymerase | ** Proofreads [[DNA polymerase]] | ||
** Functions also as a DNA-degrading enzyme in granzyme-A-mediated apoptosis | ** Functions also as a [[DNA]]-degrading enzyme in [[granzyme]]-A-mediated apoptosis | ||
** Act as a cytosolic DNA sensor | ** Act as a [[cytosolic]] [[DNA]] sensor | ||
| | | | ||
* | * Mutation lead to impairs [[DNA damage]] repair, that lead to: | ||
*# Accumulation of endogenous retroelement-derived DNA | *# Accumulation of [[endogenous]] retroelement-derived [[DNA]] | ||
*# Defective clearance of this DNA induces IFN production | *# Defective clearance of this [[DNA]] induces [[IFN-α|IFN]] production | ||
*# An immune-mediated inflammatory response | *# An [[Immune-mediated disease|immune-mediated inflammatory response]] | ||
*# Systemic autoimmunity | *# Systemic [[autoimmunity]] | ||
|- | |- | ||
!TNFSF4 | !TNFSF4 | ||
| | | | ||
* The genes in this loci produce interaction induces the production of co-stimulatory signals to activate T cells | * The [[genes]] in this loci produce interaction induces the production of co-stimulatory signals to activate [[T cells]] | ||
| | | | ||
* Inhibits the generation and function of IL-10 | * Inhibits the generation and function of [[IL-10]] producing CD4+ [[T cells]] | ||
* Induces B-cell activation and differentiation | * Induces [[B-cell]] activation and differentiation | ||
* Induces IL-17 production | * Induces [[IL17A|IL-17]] production | ||
* | * [[Mutation]] lead to predisposition to SLE: | ||
** Augmenting the interaction between T cells and antigen-presenting cells | ** Augmenting the interaction between [[T cells]] and [[antigen-presenting cells]] | ||
** Influencing the functional consequences of T-cell activation | ** Influencing the functional consequences of [[T cell|T-cell activation]] | ||
|- | |- | ||
!IL-10 | !IL-10 | ||
| | | | ||
* Encodes IL-10 | * Encodes [[IL-10]] | ||
* An important regulatory cytokine with both immunosuppressive and immunostimulatory properties | * An important [[Cytokine|regulatory cytokine]] with both [[immunosuppressive]] and [[Immunostimulator|immunostimulatory]] properties | ||
| | | | ||
* Increased IL-10 production by B cells and monocytes from patients with SLE is known to correlate with disease activity | * Increased [[IL-10]] production by [[B cells]] and [[monocytes]] from patients with SLE is known to correlate with disease activity | ||
|- | |- | ||
! rowspan="2" |Regulators of IFNα | ! rowspan="2" |Regulators of IFNα | ||
!TNFAIP3 and TNIP1 | !TNFAIP3 and TNIP1 | ||
| | | | ||
* | * Encodes key regulators of the [[NFκB]] signaling pathway | ||
* Modulate cell activation, cytokine signaling and apoptosis | * Modulate cell activation, [[cytokine]] signaling and [[apoptosis]] | ||
| | | | ||
* The exact pathogenetics is not completely known | * The exact [[Pathogenicity|pathogenetics]] is not completely known | ||
|- | |- | ||
!PHRF1 | !PHRF1 | ||
| | | | ||
* Encodes an elongation factor | * Encodes an [[elongation factor]] | ||
| | | | ||
* Related to SLE-associated autoantibodies and elevated IFN-α activity | * Related to SLE-associated [[Autoantibody|autoantibodies]] and elevated [[IFN-α]] activity | ||
|- | |- | ||
! rowspan="5" |Regulators of Lymphocytes | ! rowspan="5" |Regulators of Lymphocytes | ||
!BLK<ref name="pmid19180478">{{cite journal |vauthors=Ito I, Kawasaki A, Ito S, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Hom G, Graham RR, Takasaki Y, Hashimoto H, Ohashi J, Behrens TW, Sumida T, Tsuchiya N |title=Replication of the association between the C8orf13-BLK region and systemic lupus erythematosus in a Japanese population |journal=Arthritis Rheum. |volume=60 |issue=2 |pages=553–8 |year=2009 |pmid=19180478 |doi=10.1002/art.24246 |url=}}</ref> | !BLK<ref name="pmid19180478">{{cite journal |vauthors=Ito I, Kawasaki A, Ito S, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Hom G, Graham RR, Takasaki Y, Hashimoto H, Ohashi J, Behrens TW, Sumida T, Tsuchiya N |title=Replication of the association between the C8orf13-BLK region and systemic lupus erythematosus in a Japanese population |journal=Arthritis Rheum. |volume=60 |issue=2 |pages=553–8 |year=2009 |pmid=19180478 |doi=10.1002/art.24246 |url=}}</ref> | ||
| | | | ||
* | * Encodes a [[protein kinase]]: | ||
** Mediates | ** Mediates [[intracellular signaling]] | ||
** Influences B cells proliferation and differentiation | ** Influences [[B cells]] proliferation and differentiation | ||
** Influence tolerance of B cells | ** Influence tolerance of [[B cells]] | ||
| | | | ||
* More common in Chinese and Japanese populations | * More common in Chinese and Japanese populations | ||
|- | |- | ||
!''BANK1'' | !''BANK1'' | ||
: 11782428 | |||
:: 18204447 | |||
| | | | ||
* | * Encodes a [[B cell|B-cell]] adaptor protein | ||
* Facilitates the release of [[intracellular]] [[calcium]] | |||
* Facilitates the release of intracellular calcium | * Alter the [[B-cell]] activation threshold | ||
* Alter the B-cell activation threshold | |||
| rowspan="2" | | | rowspan="2" | | ||
* | * Mutations lead to hyperctivation of [[B-cell receptor|B-cell receptors]] and the subsequent [[B-cell]] hyperactivity that is commonly observed in SLE | ||
|- | |- | ||
!LYN | !LYN | ||
: 18204446 | |||
| | | | ||
* Mediates B-cell activation | * Mediates [[B-cell]] activation | ||
* Mediates B-cell inhibition | * Mediates [[B-cell]] inhibition | ||
|- | |- | ||
!''ETS1'' | !''ETS1'' | ||
17967903 | |||
19838195 | |||
| | | | ||
* Negatively regulates the differentiation of B cells and type 17 T-helper cells | * Negatively regulates the differentiation of [[B cells]] and type 17 [[T-helper cells]] | ||
* Regulates lymphocytes by inhibiting the function of an important transcription factor in plasma cells | * Regulates [[Lymphocyte|lymphocytes]] by inhibiting the function of an important [[transcription factor]] in [[Plasma cell|plasma cells]] | ||
| | | | ||
|- | |- | ||
!IKZF1 | !IKZF1 | ||
: | |||
: 17357110 | |||
| | | | ||
* | * Encode a [[lymphoid]]-restricted [[transcription factor]] | ||
* Regulates: | * Regulates: | ||
** Lymphocyte differentiation and proliferation | ** [[Lymphocyte]] differentiation and proliferation | ||
** Self-tolerance through regulation of B-cell-receptor signaling | ** Self-tolerance through regulation of B-cell-receptor signaling | ||
| | | | ||
Line 300: | Line 308: | ||
!Genes involved in immune complex clearance | !Genes involved in immune complex clearance | ||
!''ITGAM'' | !''ITGAM'' | ||
19838195 | |||
| | | | ||
* | * Encode a [[protein]] that binds the [[complement]] cleavage fragment of [[C3b]] | ||
| | | | ||
* Contributed to SLE susceptibility | * Contributed to SLE susceptibility |
Revision as of 14:32, 28 July 2017
https://https://www.youtube.com/watch?v=0junqD4BLH4&wmode=transparent%7C350}} |
Systemic lupus erythematosus Microchapters |
Differentiating Systemic lupus erythematosus from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Systemic lupus erythematosus pathophysiology On the Web |
American Roentgen Ray Society Images of Systemic lupus erythematosus pathophysiology |
Directions to Hospitals Treating Systemic lupus erythematosus |
Risk calculators and risk factors for Systemic lupus erythematosus pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2] Cafer Zorkun, M.D., Ph.D. [3] Raviteja Guddeti, M.B.B.S. [4]
Overview
The pathophysiology of systemic lupus erythematosus involves the immune system. There are other factors like genetic factors, hormonal abnormalities, and environmental factors that play some roles as well. The most prominent events involving immune abnormalities are related to persistent activation of B cells and plasma cells that make auto-antibodies during disease progression. The most prominent events involving hormonal abnormalities are due to prolactin and estrogen. The most important environmental factors related to disease progression are ultraviolet (UV) light and some infections. On microscopic histopathological analysis, apoptotic keratinocytes, vacuolization of the basement membrane, and dermal mucin deposition are characteristic findings of SLE dermatitis, and active or inactive endocapillary or extracapillary segmental glomerulonephritis are characteristic findings of SLE nephritis.
Pathogenesis
The progression of systemic lupus erythematosus (SLE) involves the immune system. Nearly all of the pathological manifestation of SLE are due to antibody formation and the creation and deposition of immune complexes in different organs of the body. When the immune complexes are formed, they will deposit in different body tissues and vessels, which may lead to complement activation and more organ damage. There are other factors like genetic factors, hormonal abnormalities, and environmental factors that play some roles as well.
Immune abnormalities
Development of systemic lupus erythematosus (SLE) is the due to activation of different mechanisms that may result in auto-immunity. As a result, body tissues lose their self-tolerance. Affected patients are no longer entirely tolerant to all of their self-antigens, consequently progress to an autoimmune disease and develop auto antibodies as a response. During disease progression, B cells and plasma cells that make autoantibodies are more persistently activated and thus make more autoantibodies. These autoantibodies are targeted predominantly to intracellular nucleoprotein particles.[1][2] This increase in autoantibody production and persistence is supposed to be downregulated by anti-idiotypic antibodies or regulatory immune cells, but the massive immunologic response in SLE prevents this downregulation to take place. The most important immune abnormalities that are related to SLE development and progression are:
Signaling abnormalities
- Protein kinases are responsible for intracellular cytokine signal. Intracellular signaling is leading to various types of cell response, such as:
- Cell migration
- Cell proliferation
- Inflammatory response
- Cell signaling abnormalities will lead to:
- T and B lymphocytes cellular hyperactivity
- T and B lymphocytes hyper responsiveness
- Persistence of autoreactive T cells that would otherwise have been deleted
- Signaling abnormalities of T and B lymphocytes, may be due to:
- Increased calcium responses to antigen stimulation
- Hyperphosphorylation of cytosolic protein substrates
- Decreased nuclear factor kB
- Abnormal voltage-gated potassium channels, these channels facilitate excessive calcium entry into T cells
General
- Increased expression of specific genetic factors that may be associated with promoting autoimmunity
- Increased expression of interferon alpha (IFN-α) inducible RNA transcripts by mononuclear cells leads to elevated levels of IFN-α.[3] Increased availability of stimulatory nucleic acids would implicate IFN-I production, that is responsible for chronic and recurrent characteristics of the SLE.
- Elevated levels of circulating TNF-alpha correlate with active disease, and TNF is expressed in renal tissue in lupus nephritis
- Abnormally high levels of CD4 on erythrocytes (E-CD4) and low levels of erythrocyte complement receptor type one (E-CR1) are characteristic of SLE, and combined measurement of the 2 molecules has high diagnostic sensitivity and specificity for lupus
Neutrophil
- Increased number of circulating neutrophils undergoing NETosis (NET=neutrophil extracellular traps), a form of apoptosis specific for neutrophils, releases DNA bound to protein in protein nets, which stimulates anti-DNA and IFN-alpha production
- Increased neutrophil extracellular trap leads to: [4]
- thrombus formation
- Increased disease activity and renal disease and thus can be used even as a disease activity marker
- Endothelial cell damage and inflammation in atherosclerotic plaques, which may contribute to accelerated atherosclerosis in systemic lupus erythematosus
Microparticles
- Increased level of microparticles (MPs):
- Microparticles are small, membrane-bound vesicles enclose DNA, RNA, nuclear proteins, cell adhesion molecules, growth factors, and cytokines
- They are shed from cells during apoptosis or activation
- Microparticles can drive inflammation and autoimmunity by their derivatives[5]
- Increase in circulating plasma cells and memory B cells that is associated with SLE activity
- Polyclonal activation of B cells and abnormal B-cell receptor signaling
- Increase in B cells life span
- Decrease in cytotoxic T cells, decrease in suppressor T cell's function, and impaired generation of polyclonal T-cell cytolytic activity
- Increased number and activity of helper T cells
- As an example of immune abnormalities and their complications, nervous system involvement in SLE is due to:
- Small to moderate sized vessels vasculopathy with perivascular accumulation of mononuclear cells, without destruction of the blood vessel
- Antiphospholipid antibodies
- These changes promote the production of antinuclear antibodies
Hormonal abnormalities
The following evidence is suggestive of the hormonal predisposition to SLE:
- Sexual predilection for females, shows the relationship of female hormones and the onset of SL
- Significantly increased risk for SLE in:[6]
- Early age of menarche
- Early age at menopause or surgical menopause
- Women that are treated with estrogen-containing regimens such as oral contraceptives or postmenopausal hormone replacement therapies
Hormones that are related to disease progression:[7]
- Prolactin:
- Stimulates the immune system and is elevated in SLE
- Exogenous estrogen - including oral contraceptive use and postmenopausal hormone replacement therapy: [7][8]
- Stimulates the type 1 IFN pathway
- Stimulates thymocytes, CD8+ and CD4+ T cells, B cells, macrophages, and causes the release of certain cytokines (eg, IL-1)
- Prompt maturation of B cells, especially those that have a high affinity to anti-DNA antibodies by decreasing the apoptosis of self-reactive B-cells[9]
- Stimulate expression of HLA and endothelial cell adhesion molecules (VCAM, ICAM)
- Increases macrophage proto-oncogene expression
- Enhanced adhesion of peripheral mononuclear cells to endothelium
- Progesterone:
- May inhibit the type 1 interferon pathway, suggesting that a balance between estrogen and progesterone may be critical for the body to remain healthy
- Down-regulates T-cell proliferation and increases the number of CD8 cells
- Both progesterone and high levels of estrogen promote a Th2 response, which favors autoantibody production
Environmental factors
- Infections can stimulate some antigen specific cells and lead to SLE:
- Epstein-Barr virus (EBV): May induce anti-DNA antibodies or even lupus-like symptoms. It is associated with higher risk of SLE and also triggering the active course of disease in children.
- Trypanosomiasis or mycobacterial infections may have the same effect as EBV.
- SLE flares may follow bacterial infections as well.
- Ultraviolet (UV) light:
- Can stimulate B-cells to produce more antibodies.
- It can also interfere with antigen processing by activation of macrophages and hence increase the degree of autoimmunity.
Lupus nephritis
In the initial phase of the disease, the immune deposits and/or autoantibodies induce cytokine production in renal resident cells, leading to further inflammatory cytokine/chemokine expression and leukocyte infiltration and activation. Then, infiltrate leukocytes, such as macrophages (Mφ) and dendritic cells (DCs), secrete a variety of cytokines and activate naïve T cells, leading the cytokine profile towards T helper (Th)1, Th2, and/or Th17.
The current paradigm is that LN results from immune complex deposition in the renal glomeruli leading to complement activation, chronic inflammation and renal insufficiency defined by histopathology and the presence of proteinuria and cellular casts.Genetics
Systemic lupus erythematosus is transmitted in polygenic inheritance pattern. Genes involved in the pathogenesis of systemic lupus erythematosus include HLA class 2 especially DR2 nd DR3, HLA class 3 especially complement genes include C2 and C4 genes, IFNRF5 gene, and other genes related to immunologic system as well.
The following evidence is also suggestive of the genetic predisposition of SLE:[10]
- Increase of disease occurrence in identical twins
- Increased disease frequency among first degree relatives
- The increased risk of developing the disease in siblings of SLE patients
Classification | Gene subtype | Function | Pathological effect and Molecular mechanisms |
---|---|---|---|
HLA | HLA class2[11] |
|
|
HLA class3[12] |
|
| |
Non-HLA | Interferon (IFN) regulatory factor 5[13] |
|
|
STAT4[14][15][16][17] |
|
| |
PTPN22[18] |
|
| |
FcγR genes[19] |
|
| |
C1q genes[12] |
|
| |
The IRAK1-MECP2 region |
|
||
TREX1 |
|
| |
TNFSF4 |
| ||
IL-10 |
|
||
Regulators of IFNα | TNFAIP3 and TNIP1 |
| |
PHRF1 |
|
| |
Regulators of Lymphocytes | BLK[20] |
|
|
BANK1
|
|
| |
LYN
|
|||
ETS1
17967903 19838195 |
|
||
IKZF1
|
|
| |
Genes involved in immune complex clearance | ITGAM
19838195 |
|
|
Associated Conditions
- Homozygous deficiencies of the components of complement especially C1q are associated with developing immunologic diseases especially SLE or a lupus-like disease.[21]
- The FcγRIIA polymorphism has been associated with nephritis in African Americans, Koreans, and Hispanics. Both FcgammaRIIa and FcgammaRIIIa have low binding alleles that confer risk for SLE and may act in the pathogenesis of disease. [22]
- Women treated with estrogen-containing regimens such as oral contraceptives or postmenopausal hormone replacement therapies are more predisposed to SLE.
- Annular or psoriasiform skin lesions are associated with anti-Ro (SS-A) and anti-La (SS-B) antibodies.
- Anti-Ro, anti-La, anti sm, and anti RNP antibodies have been associated with mucocutaneous involvement and less severe nephropathy.
Gross Pathology
On gross pathology of kidney, bilateral pallor, and hypertrophy of kidneys are characteristic findings of systemic lupus erythematosus.
On gross pathology of brain, infarct regions and hemorrhages are characteristic findings of systemic lupus erythematosus.
On gross pathology of cardiac valves, cardiomegaly and valvular vegetation are characteristic findings of systemic lupus erythematosus.
On gross pathology of pleura, pleuritis and pleural fibrosis are characteristic findings of systemic lupus erythematosus.
Microscopic Pathology
On microscopic histopathological analysis, apoptotic keratinocytes, vacuolization of the basement membrane, and dermal mucin deposition are characteristic findings of SLE dermatitis, and active or inactive endocapillary or extracapillary segmental glomerulonephritis are characteristic findings of SLE nephritis.
Skin involvement histopathology:
Common shared histopathologic features among all different subtypes of cutaneous lupus include:
- Hyperkeratosis
- Epidermal atrophy
- Dermal mucin deposition
- Liquefactive degeneration of the basal layer of the epidermis and vacuolization
- Thickening of the basement membrane
- Pigment incontinence
- Mononuclear cell infiltration at dermo-epidermal junction
- Superficial, perivascular, and perifollicular areas (due to mononuclear cell inflammatory infiltrate)
SLE dermatitis subtype | Specific microscopic findings |
---|---|
Acute cutaneous lupus erythematosus |
|
Subacute cutaneous lupus erythematosus |
|
Chronic cutaneous lupus erythematosus |
|
Glomerulonephritis histopathology:
Class | SLE nephritis subtype | Light microscopy findings | Electron microscopy/Immunofluorescence findings |
---|---|---|---|
I | Minimal mesangial lupus nephritis | - |
|
II | Mesangial proliferative lupus nephritis |
|
|
III | Focal lupus nephritis |
|
|
IV | Diffuse lupus nephritis |
|
|
V | Lupus membranous nephropathy |
|
|
VI | Advanced sclerosing lupus nephritis |
|
Synovial involvement histopathology
- Nonspecific histopathologic findings
- Superficial fibrin-like material
- Local or diffuse synovial cell lining proliferation
- Vascular changes:
- Perivascular mononuclear cells
- Lumen obliteration
- Enlarged endothelial cells
- Thrombi
Mucosal involvement histopathology
- Hyperkeratosis
- Atrophy of rete processes
- Superficial and deep inflammatory infiltrates
- Edema in the lamina propria
- Continuous or patchy periodic acid-Schiff (PAS)-positive deposits in the basement membrane zone
- Deposition of intercellular mucin
- Deposition of immunoglobulin and complement at the dermal-epidermal junction
Videos
{{#ev:youtube|Tw07BFaDEo0}}
References
- ↑ Elkon K (1995). "Autoantibodies in systemic lupus erythematosus". Curr Opin Rheumatol. 7 (5): 384–8. PMID 8519610.
- ↑ Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, Komisar O, Slonimsky E, Klang E, Lotan E, Welt M, Marai I, Shina A, Amital H, Shoenfeld Y (2015). "A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients". Autoimmun Rev. 14 (1): 75–9. doi:10.1016/j.autrev.2014.10.003. PMID 25449682.
- ↑ Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, Ly N, Woodward RN, Fry KE, Lau AY, Prentice JG, Wohlgemuth JG, Crow MK (2004). "Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus". Arthritis Rheum. 50 (12): 3958–67. doi:10.1002/art.20798. PMID 15593221.
- ↑ Barnado A, Crofford LJ, Oates JC (2016). "At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases". J. Leukoc. Biol. 99 (2): 265–78. doi:10.1189/jlb.5BT0615-234R. PMID 26658004.
- ↑ Dye JR, Ullal AJ, Pisetsky DS (2013). "The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus". Scand. J. Immunol. 78 (2): 140–8. doi:10.1111/sji.12068. PMID 23672591.
- ↑ Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW (2007). "Reproductive and menopausal factors and risk of systemic lupus erythematosus in women". Arthritis Rheum. 56 (4): 1251–62. doi:10.1002/art.22510. PMID 17393454.
- ↑ 7.0 7.1 Lahita RG (1999). "The role of sex hormones in systemic lupus erythematosus". Curr Opin Rheumatol. 11 (5): 352–6. PMID 10503654.
- ↑ Hughes GC, Choubey D (2014). "Modulation of autoimmune rheumatic diseases by oestrogen and progesterone". Nat Rev Rheumatol. 10 (12): 740–51. doi:10.1038/nrrheum.2014.144. PMID 25155581.
- ↑ Cohen-Solal JF, Jeganathan V, Grimaldi CM, Peeva E, Diamond B (2006). "Sex hormones and SLE: influencing the fate of autoreactive B cells". Curr. Top. Microbiol. Immunol. 305: 67–88. PMID 16724801.
- ↑ Sullivan KE (2000). "Genetics of systemic lupus erythematosus. Clinical implications". Rheum. Dis. Clin. North Am. 26 (2): 229–56, v–vi. PMID 10768211.
- ↑ Lee HS, Chung YH, Kim TG, Kim TH, Jun JB, Jung S, Bae SC, Yoo DH (2003). "Independent association of HLA-DR and FCgamma receptor polymorphisms in Korean patients with systemic lupus erythematosus". Rheumatology (Oxford). 42 (12): 1501–7. doi:10.1093/rheumatology/keg404. PMID 12867584.
- ↑ 12.0 12.1 Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ (2000). "Systemic lupus erythematosus, complement deficiency, and apoptosis". Adv. Immunol. 76: 227–324. PMID 11079100.
- ↑ Löfgren SE, Yin H, Delgado-Vega AM, Sanchez E, Lewén S, Pons-Estel BA, Witte T, D'Alfonso S, Ortego-Centeno N, Martin J, Alarcón-Riquelme ME, Kozyrev SV (2010). "Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to systemic lupus erythematosus in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells". J. Rheumatol. 37 (3): 574–8. doi:10.3899/jrheum.090440. PMID 20080916.
- ↑ Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O, Eloranta ML, Gunnarsson I, Svenungsson E, Sturfelt G, Bengtsson AA, Jönsen A, Truedsson L, Rantapää-Dahlqvist S, Eriksson C, Alm G, Göring HH, Pastinen T, Syvänen AC, Rönnblom L (2008). "A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5". Hum. Mol. Genet. 17 (18): 2868–76. doi:10.1093/hmg/ddn184. PMC 2525501. PMID 18579578.
- ↑ Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB (2009). "Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo". J. Immunol. 182 (1): 34–8. PMC 2716754. PMID 19109131.
- ↑ Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA (2008). "Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus". PLoS Genet. 4 (5): e1000084. doi:10.1371/journal.pgen.1000084. PMC 2377340. PMID 18516230.
- ↑ Kawasaki A, Ito I, Hikami K, Ohashi J, Hayashi T, Goto D, Matsumoto I, Ito S, Tsutsumi A, Koga M, Arinami T, Graham RR, Hom G, Takasaki Y, Hashimoto H, Behrens TW, Sumida T, Tsuchiya N (2008). "Role of STAT4 polymorphisms in systemic lupus erythematosus in a Japanese population: a case-control association study of the STAT1-STAT4 region". Arthritis Res. Ther. 10 (5): R113. doi:10.1186/ar2516. PMC 2592800. PMID 18803832.
- ↑ Gregersen PK, Olsson LM (2009). "Recent advances in the genetics of autoimmune disease". Annu. Rev. Immunol. 27: 363–91. doi:10.1146/annurev.immunol.021908.132653. PMC 2992886. PMID 19302045.
- ↑ Yap SN, Phipps ME, Manivasagar M, Tan SY, Bosco JJ (1999). "Human Fc gamma receptor IIA (FcgammaRIIA) genotyping and association with systemic lupus erythematosus (SLE) in Chinese and Malays in Malaysia". Lupus. 8 (4): 305–10. doi:10.1191/096120399678847876. PMID 10413210.
- ↑ Ito I, Kawasaki A, Ito S, Hayashi T, Goto D, Matsumoto I, Tsutsumi A, Hom G, Graham RR, Takasaki Y, Hashimoto H, Ohashi J, Behrens TW, Sumida T, Tsuchiya N (2009). "Replication of the association between the C8orf13-BLK region and systemic lupus erythematosus in a Japanese population". Arthritis Rheum. 60 (2): 553–8. doi:10.1002/art.24246. PMID 19180478.
- ↑ Petry F, Botto M, Holtappels R, Walport MJ, Loos M (2001). "Reconstitution of the complement function in C1q-deficient (C1qa-/-) mice with wild-type bone marrow cells". J. Immunol. 167 (7): 4033–7. PMID 11564823.
- ↑ Li R, Peng H, Chen GM, Feng CC, Zhang YJ, Wen PF, Qiu LJ, Leng RX, Pan HF, Ye DQ (2014). "Association of FCGR2A-R/H131 polymorphism with susceptibility to systemic lupus erythematosus among Asian population: a meta-analysis of 20 studies". Arch. Dermatol. Res. 306 (9): 781–91. doi:10.1007/s00403-014-1483-5. PMID 24997134.
- ↑ Sepehr A, Wenson S, Tahan SR (2010). "Histopathologic manifestations of systemic diseases: the example of cutaneous lupus erythematosus". J. Cutan. Pathol. 37 Suppl 1: 112–24. doi:10.1111/j.1600-0560.2010.01510.x. PMID 20482683.